Semler Scientific

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Semler Scientific posts record revenue and profit growth in Q4

Semler Scientific delivered robust financial performance in Q4 2022, marked by record revenue, profit growth, and a strong cash position.
The company's strengths lie in its revenue diversification, profitability improvement, and strategic leadership transition.
Challenges include managing operating expenses, sustaining revenue growth across segments, and ensuring a smooth CEO transition.
Opportunities for Semler include expansion, innovation in healthcare technologies, and leveraging market demand for its services for future growth.

Semler Scientific achieves record Q1 earnings amidst strategic growth

Semler Scientific delivered robust financial performance in Q1 2023, marked by record revenue and pre-tax net income, underpinned by strong liquidity.
The company's strategic focus on governance, product innovation, and confidence in product benefits positions it well to navigate challenges and seize growth opportunities.
Despite cost management challenges and regulatory uncertainties, Semler's resilience, financial strength, and commitment to innovation bode well for future success.

Semler Scientific reports record revenue and profit growth in Q2

Semler Scientific's Q2 2023 performance showcased robust revenue growth, driven by successful QuantaFlo sales, and a significant increase in pre-tax net income.
The company's strategic initiatives, including leadership changes, product introductions, and operational streamlining, demonstrate a focus on sustainable growth and innovation.
While facing challenges such as cost management and workforce reduction, Semler Scientific is well-positioned to leverage opportunities in market expansion, technology advancements, and clinical benefits delivery.

Semler Scientific excels in Q3 with strong revenue growth

Semler Scientific's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and growth opportunities. The company's focus on innovation and market expansion positions it well for future success.

Semler Scientific reports solid Q4 earnings, eyes growth in cardiovascular diagnosis

Semler Scientific's Q4 2023 earnings call showcased positive financial performance, strategic growth initiatives, and a commitment to innovation in cardiovascular disease diagnosis.
Despite challenges such as operating expenses and fixed fee revenue decline, the company's adaptability and focus on clinical benefits position it well for future opportunities.
Analyst inquiries and executive responses highlighted a strong emphasis on efficiency improvements, market adaptability, and regulatory clearances for continued growth.

Semler Scientific reports earnings growth, eyes new product clearance

Semler Scientific's Q1 2024 performance showed growth in earnings and effective cost management.
While facing revenue challenges, the company is strategically positioned to capitalize on growth opportunities.
With a focus on innovation and market expansion, Semler aims to drive future revenue growth.
The company's strong financial position and strategic initiatives position it well for future success.

Semler Scientific adopts bitcoin treasury, reports stable Q2 performance

Semler Scientific's Q2 2024 performance reflects a strategic shift towards bitcoin as a treasury asset and a focus on core business operations.
While facing revenue challenges and cost management needs, the company's financial strength and flexibility position it well for future growth.
Opportunities lie in leveraging debt securities for expansion and capitalizing on the potential of bitcoin as a long-term investment.

Semler Scientific reports robust Q3 earnings, diversifies into Bitcoin

Semler Scientific's Q3 2024 performance reflects resilience in income generation and prudent cost control measures.
The company's strategic focus on Bitcoin acquisitions and product innovation positions it for potential growth and market leadership.
While facing revenue challenges and financial risks, Semler's exploration of financing options and regulatory compliance efforts signal a proactive stance.
Opportunities lie in leveraging operational strength for expansion, diversifying investment strategies, and capitalizing on early disease diagnosis capabilities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

SMLR has a competitive product (QuantaFlo) in the cardiovascular diagnostic space, and is currently awaiting a 510(k) clearance for expanded use, which could potentially arrive in H2-24. Semler's cash generating prowess has picked up over time, and currently 73% of its asset base consists of cash alone. P/E Valuations are cheap, and buyback momentum is likely to step up.

Semler Scientific: Not Perfect But Worth Considering

SANTA CLARA, Calif. , April 23, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial markets on Tuesday, May 7, 2024.

Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024

AMN Healthcare Services

Bristol-Myers

CVS Health

Patterson Companies

Royalty Pharma

Voyager Therapeutics

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

Semler Scientific, Inc. (NASDAQ:SMLR ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Renae Cormier - Chief Financial Officer Jennifer Oliva Herrington - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Fourth Quarter Financial Results Conference Call. All participants will be in a listen-only mode [Operator Instructions].

Semler Scientific, Inc. (SMLR) Q4 2023 Earnings Call Transcript

2023 Q4 and full year highlights compared to the corresponding period of 2022: Fourth quarter revenues were $15.1 million, an increase of 9% Fourth quarter net income was $4.2 million, an increase of 31% Full year revenues were $68.2 million, an increase of 20% Full year net income was $20.6 million, an increase of 44% Cash balance increased to $57.3 million SANTA CLARA, Calif. , March 5, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results

SANTA CLARA, Calif. , Feb. 21, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023, after the close of U.S. financial markets on Tuesday, March 5, 2024.

Semler Scientific to Report Fourth Quarter and Year End 2023 Financial Results and Host Conference Call on March 5, 2024

Semler is a medtech company with high ROC, double-digit top-line growth, and a robust balance sheet. The company operates in the cardiovascular testing industry, primarily marketing the QuantaFlo blood flow assessment tool. Semler faces risks such as patent expiration, customer dependency, and product dependency, but the stock is still a buy due to its low price.

Semler Scientific Offers Great Potential, But Don't Overlook The Risks

Terran Orbital Corp

Riot Blockchain

The recent sell-off in tech stocks has left many high-quality names trading at sizable discounts. For long-term investors, this presents an intriguing opportunity to position one's portfolio for the next bull market.

3 Millionaire-Maker Tech Stocks That Could Soar Over 1,000%

Semler Scientific, Inc. (NASDAQ:SMLR ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Doug Murphy-Chutorian – Chief Executive Officer Renae Cormier – Chief Financial Officer Jennifer Oliva Herrington – Chief Operating Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Herbert Semler – Semler Health Operator Good afternoon, and welcome to the Semler Scientific 2023 Third Quarter Financial Results Conference Call. All participants will be in a listen-only mode.

Semler Scientific, Inc. (SMLR) Q3 2023 Earnings Call Transcript

2023 Q3 highlights: Revenue of $16.3 million, an increase of 16% compared to the corresponding period of 2022 Net income of $5.5 million, an increase of 50% compared to the corresponding period of 2022 Quarter-ending cash, cash equivalents and short-term investments of $56.0 million SANTA CLARA, Calif. , Nov. 9, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three and nine months ended September 30, 2023.

Semler Scientific Reports Third Quarter and Year-to-Date 2023 Financial Results

SANTA CLARA, Calif. , Oct. 26, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the third quarter and first nine months ended September 30, 2023, after the close of U.S. financial markets on Thursday, November 9, 2023.

Semler Scientific to Report Third Quarter and First Nine Months of 2023 Financial Results and Host Conference Call on November 9, 2023

Semler Scientific's 1H 2023 was surprisingly strong, with record high fixed-fee and variable-fee revenues. Semler's strong financial performance stands in stark contrast to its stock price, which has languished at a price even below where it was during the pandemic. Short-term, the market is concerned that the Hierarchical Condition Categories (HCC) codes effective in 2024 will reimburse QuantaFlo at a lower clip than in previous years.

Semler Scientific: The Business Is So Stellar That I'm Willing To Overlook Yellow Flags

SANTA CLARA, Calif. , Aug. 31, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced Renae Cormier, CFO, will participate in the following investor conference: Lake Street Capital Markets 7th Annual Best Ideas Growth (BIG7) Conference Date: September 14, 2023 Format: One-on-one meetings About Semler Scientific, Inc.: Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases.

Semler Scientific to Present at Upcoming Investor Conference

Start Time: 16:30 January 1, 0000 4:49 PM ET Semler Scientific, Inc. (NASDAQ:SMLR ) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO Renae Cormier - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode.

Semler Scientific, Inc. (SMLR) Q2 2023 Earnings Call Transcript

2023 Q2 highlights: Revenue was $18.6 million, an increase of 25% compared to the corresponding period of 2022 Net income was $5.9 million, an increase of 44% compared to the corresponding period of 2022 Cash, cash equivalents and short-term investments of $51.8 million SANTA CLARA, Calif. , Aug. 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three and six months ended June 30, 2023.

Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results

Michael Burry is a renowned American investor and hedge fund manager. He gained fame for his successful bets against the U.S. housing market before the 2008 financial crisis. He is known for his contrarian investment approach and his investment strategy often focuses on "roadkill" companies, or those trading at heavily discounted prices due to being out of favor. His strategy focuses on small companies, downside protection, low EV/EBITDA ratios, and resilient industries.

Semler Scientific Is The Roadkill Your Portfolio Is Asking For

SANTA CLARA, Calif. , July 28, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of U.S. financial markets on Thursday, August 10, 2023.

Semler to Report Second Quarter 2023 Financial Results and Host Conference Call on August 10, 2023

SMLR has shown strong financial performance over the past decade, and the company's long-term prospects also look bright. Cardiovascular diseases are still the biggest cause of global deaths meaning there is vast room for improvement and investment in this industry. A valuation analysis using a discounted cash flow approach suggests that the stock is massively undervalued.

Semler Scientific: A High-Quality, Cash Rich Microcap

SANTA CLARA, Calif. , July 11, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining.

Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining

SANTA CLARA, Calif. , June 23, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.

Semler Scientific to Join the Russell 2000® and 3000® Indexes

Hibbett Sports

Inogen

Vimeo

Cara Therapeutics

1-800-FLOWERS.COM

NerdWallet

While the traditional approach to market success calls for patiently investing in reliable blue chips, those that want to see more immediate gains may consider small-cap stocks to buy. Here, the point is about accepting massive risk to hopefully realize massive rewards.

Hero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich

Semler Scientific, Inc. (NASDAQ:SMLR ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Douglas Murphy-Chutorian - Interim Chief Executive Officer Renae Cormier - Head of Corporate Communications and Business Strategy Andrew Weinstein - Senior Vice President, Finance and Accounting Dennis Rosenberg - Chief Marketing Officer Conference Call Participants Operator Good afternoon, and welcome to the Semler Scientific 2023 First Quarter Financial Results Conference Call. All participants will be in a listen-only mode.

Semler Scientific, Inc. (SMLR) Q1 2023 Earnings Call Transcript

2023 Q1 highlights: Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022 Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022 Cash, cash equivalents and short-term investments of $43.0 million SANTA CLARA, Calif. , May 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three months ended March 31, 2023.

Semler Scientific Reports First Quarter 2023 Financial Results

SANTA CLARA, Calif. , May 1, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the first quarter ended March 31, 2023, after the close of U.S. financial markets on Wednesday, May 10, 2023.

Semler to Report First Quarter 2023 Financial Results and Host Conference Call on May 10, 2023

SANTA CLARA, Calif. , April 28, 2023 /PRNewswire/ -- The board of directors of Semler Scientific, Inc. (Nasdaq: SMLR), is pleased to announce that it has appointed Doug Murphy-Chutorian, M.D.

News for Semler Scientific Stock (SMLR)